[go: up one dir, main page]

MX2010006719A - Compuestos y metodos para el tratamiento de enfermedad vascular. - Google Patents

Compuestos y metodos para el tratamiento de enfermedad vascular.

Info

Publication number
MX2010006719A
MX2010006719A MX2010006719A MX2010006719A MX2010006719A MX 2010006719 A MX2010006719 A MX 2010006719A MX 2010006719 A MX2010006719 A MX 2010006719A MX 2010006719 A MX2010006719 A MX 2010006719A MX 2010006719 A MX2010006719 A MX 2010006719A
Authority
MX
Mexico
Prior art keywords
treatment
disease
vascular
vascular disease
dysfunction
Prior art date
Application number
MX2010006719A
Other languages
English (en)
Inventor
Johan Frostegard
Knut Pettersson
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of MX2010006719A publication Critical patent/MX2010006719A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con un método para el tratamiento de disfunción vascular, reducir dolor isquémico y/o tratamiento de una enfermedad vascular que comprende administrar una cantidad terapéuticamente eficaz de anexina A5 o un análogo funcional o una variante de la misma a un paciente en necesidad de dicho tratamiento; la disfunción vascular, el dolor isquémico y/o la enfermedad vascular se pueden asociar con vasodilatación deteriorada mediada por endotelio, una actividad reducida de eNOS y/o una biodisponibilidad reducida de NO; el paciente puede padecer de una enfermedad que se selecciona de angina de pecho, cardiopatía isquémica, arteriopatía periférica, hipertensión sistólica, migraña, diabetes tipo 2 y disfunción eréctil.
MX2010006719A 2007-12-18 2008-12-18 Compuestos y metodos para el tratamiento de enfermedad vascular. MX2010006719A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1459407P 2007-12-18 2007-12-18
PCT/GB2008/004195 WO2009077764A1 (en) 2007-12-18 2008-12-18 Compounds and methods for the treatment of vascular disease

Publications (1)

Publication Number Publication Date
MX2010006719A true MX2010006719A (es) 2010-09-28

Family

ID=40419062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006719A MX2010006719A (es) 2007-12-18 2008-12-18 Compuestos y metodos para el tratamiento de enfermedad vascular.

Country Status (16)

Country Link
US (3) US8809497B2 (es)
EP (1) EP2234631B1 (es)
JP (1) JP2011506590A (es)
KR (1) KR20100105652A (es)
CN (1) CN102223892A (es)
AU (1) AU2008337284B2 (es)
BR (1) BRPI0821272A2 (es)
CA (1) CA2708956C (es)
DK (1) DK2234631T3 (es)
ES (1) ES2393163T3 (es)
HR (1) HRP20120797T1 (es)
MX (1) MX2010006719A (es)
PL (1) PL2234631T3 (es)
PT (1) PT2234631E (es)
SI (1) SI2234631T1 (es)
WO (1) WO2009077764A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2254589T3 (pl) 2008-02-22 2017-11-30 Annexin Pharmaceuticals Ab Związki i sposoby zapobiegania lub leczenia restenozy
CN102256617B (zh) 2008-10-17 2015-04-08 伦敦健康科学中心研究公司 膜联蛋白及其治疗炎性病症的用途
PL2694538T3 (pl) 2011-04-05 2017-04-28 Annexin Pharmaceuticals Ab Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5
PL2668947T3 (pl) * 2012-05-31 2017-06-30 G. Pohl-Boskamp Gmbh & Co. Kg Indukcja arteriogenezy donorem NO, takim jak nitrogliceryna
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
CN111494608A (zh) * 2020-05-08 2020-08-07 北京大学第三医院（北京大学第三临床医学院） 预防或治疗子痫前期及相关病症的药物及其应用
JP7789809B2 (ja) 2021-06-14 2025-12-22 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 突然変異アネキシンａ５ポリペプチドおよび治療目的のその使用
WO2025086968A1 (zh) * 2023-10-25 2025-05-01 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007338A (es) 2001-02-15 2005-06-06 King Pharmaceuticals Inc Fabricacion de tabletas de hormona tiroidea que tienen cantidades consistentes de la porcion activa.
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
CA2479187A1 (en) 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
US20040022731A1 (en) * 2002-04-26 2004-02-05 Alexei Bogdanov In vivo imaging of apoptosis
AU2003237351B2 (en) * 2002-06-06 2009-12-03 Tze Chein Wun Novel recombinant anticoagulant proteins
US20060029668A1 (en) * 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
WO2005018436A2 (en) 2003-08-26 2005-03-03 The Trustees Of Boston University Methods for the diagnosis, prognosis and treatment of metabolic syndrome
EP1675619A4 (en) 2003-09-29 2010-10-06 Palmetto Pharmaceuticals Llc EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES
US20080044404A1 (en) 2004-04-15 2008-02-21 Anna Cederholm Annexin V for Preventing Atherothrombosis and Plaque Rupture
US20050267030A1 (en) * 2004-04-30 2005-12-01 Tsao Philip S Use of deltaPKC peptides for modulation of reactive oxygen species
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
EP1784483A2 (en) 2004-08-02 2007-05-16 The Board Of Trustees Of The Leland Stanford Junior University Peptide sequence for modulation of delta protein kinase c
JP4949661B2 (ja) * 2004-09-21 2012-06-13 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
WO2006033287A1 (ja) * 2004-09-21 2006-03-30 Sankyo Company, Limited ＨＭＧ－ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物。
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
ES2617002T3 (es) 2005-12-12 2017-06-15 Mosamedix B.V. Derivados de anexina adecuados para la prefocalización en terapia y diagnóstico

Also Published As

Publication number Publication date
HRP20120797T1 (hr) 2012-12-31
WO2009077764A1 (en) 2009-06-25
BRPI0821272A2 (pt) 2015-06-16
AU2008337284B2 (en) 2014-09-18
JP2011506590A (ja) 2011-03-03
CA2708956A1 (en) 2009-06-25
DK2234631T3 (da) 2013-01-07
PT2234631E (pt) 2012-11-20
PL2234631T3 (pl) 2013-03-29
CA2708956C (en) 2018-07-17
AU2008337284A1 (en) 2009-06-25
US20160235811A1 (en) 2016-08-18
SI2234631T1 (sl) 2013-02-28
ES2393163T3 (es) 2012-12-19
CN102223892A (zh) 2011-10-19
EP2234631A1 (en) 2010-10-06
US8809497B2 (en) 2014-08-19
KR20100105652A (ko) 2010-09-29
US9649355B2 (en) 2017-05-16
US9682122B2 (en) 2017-06-20
US20150010531A1 (en) 2015-01-08
US20100291064A1 (en) 2010-11-18
EP2234631B1 (en) 2012-09-12

Similar Documents

Publication Publication Date Title
MX2010006719A (es) Compuestos y metodos para el tratamiento de enfermedad vascular.
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2007029249A3 (en) Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases
WO2009020643A3 (en) Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue
SG148850A1 (en) Methods of treating vascular disease
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MX336710B (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2006020581A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
WO2008066626A3 (en) METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
WO2007143185A3 (en) Transdermal treatment of tendinopathy using glyceryl trinitrite
WO2009150214A3 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
PL1680112T3 (pl) N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2010022326A3 (en) Transdermal delivery of apomorphine using microneedles
WO2006045314A3 (en) Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
NZ597957A (en) Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients